Clinical Studies

At Moleac, understanding the properties of our innovations is one of our priorities. We keep investing heavily in research and development to fully use the potential of our product in neurology. Moleac has worked with world renowned experts in over 20 research centers. Below is a full list of clinical studies we have been supporting.

For more information about the clinical studies we are involved in please contact our medical team at medical@moleac.com

Ischemic Stroke
NeuroAiD Danqi Piantang Jiaonang Does Not Modify Hemostasis, Hematology, and Biochemistry in Normal Subjects and Stroke Patients.

Publication : Gan R, et al. Cerebrovasc Dis 2008. DOI: 10.1159/000126919

Participation Size : 64

NeuroAiD in Stroke Recovery.

Publication : Siow C, Eur Neurol 2008. DOI: 10.1159/000155220

Participation Size : 10

Ischemic Stroke
A Double-Blind, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of the Traditional Chinese Medicine NeuroAiD (MLC601) in Enhancing Recovery after Stroke (TIERS).

Publication : Kong KH, et al. Cerebrovasc Dis 2009.DOI: 10.1159/000247001

Participation Size : 40

Sponsor : Moleac Pte Ltd.

NeuroAiD (Danqi Piantang Jiaonang), a Traditional Chinese Medicine, in Poststroke Recovery.

Publication : Chen C, et al. Stroke 2009. DOI: 10.1161/STROKEAHA.108.531616

Participation Size : 605

Sponsor : Tianjin University of Traditional Chinese Medicine

Traumatic Brain Injury - Neurosurgical pathologies
Case Report on the Use of MLC601 (NeuroAiD) in Neurosurgical Pathologies.

Publication : Yeo TT, et al. Poster WSC Seoul 2010.

Participation Size : 3

Ischemic Stroke
The effect of NeuroAiD (MLC601) on cerebral blood flow velocity in subjects’ post brain infarct in the middle cerebral artery territory.

Publication : Shahripour RB, et al. Eur Intern Med 2011. DOI: 10.1016/j.ejim.2011.01.002

Participation Size : 80

NeuroAiD (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia.

Publication : Ghandehari K, et al. Neural Regen Res 2011. DOI: 10.3969/j.issn.1673-5374.2011.06.003

Participation Size : 40

Sponsor : Moleac Pte. Ltd.

Ischemic Stroke
The Use of NeuroAiD (MLC601) in Post ischemic Stroke Patients.

Publication : Navarro JC, et al. Rehabil Res Pract 2012. DOI: 10.1155/2012/506387

Participation Size : 30

Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial.

Publication : Harandi AA, et al. Stroke Res Treat 2011. DOI: 10.4061/2011/721613

Participation Size : 150

Sponsor : Shahid Beheshti University

Ischemic Stroke
Chinese Medicine Neuroaid Efficacy on Stroke Recovery: A Double-Blind, Placebo-Controlled, Randomized Study.

Publication : Chen C, et al. Stroke 2013. DOI: 10.1161/STROKEAHA.113.002055

Participation Size : 1099

Sponsor : CHIMES Society

Cognitive Disorders and Dementia
Efficacy and Tolerability of MLC601 in Patients with Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.

Publication : Harandi AA, et al. Brit Med Med Res 2013.

Participation Size : 124

Sponsor : Shahid Beheshti University of Medical Sciences

Ischemic Stroke
A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke.

Publication : Shahripour RB, et al. Chin J Integr Med 2014. DOI: 10.1007/s11655-014-1687-8

Participation Size : 150

Ischemic Stroke
CHInese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy.

Publication : Venketasubramanian N, et al. Cerebrovascular Diseases 2015. DOI: 10.1159/000382082

Participation Size : 880

Sponsor : CHIMES Society

Cognitive Disorders and Dementia
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer’s Disease: A Multicenter, Randomized Controlled Trial.

Publication : Pakdaman, H et al. Dementia and Geriatric Cognitive Disorders 2015. DOI: 10.1159/000375295

Participation Size : 264

Ischemic Stroke
NurAiD-II in stroke recovery: scientific reasoning and real-world evidence.

Publication : De Le Cruz Cosme C. International Journal of Clinical Neurosciences and Mental Health 2017.

Cognitive Disorders and Dementia
MLC601 in vascular dementia: an efficacy and safety pilot study.

Publication : Pakdaman H, et al. Neuropsychiatric Disease and Treatment 2017. DOI: 10.2147/NDT.S145047

Participation Size : 81

Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study.

Publication : Pakdaman H, et al. Dementia and Geriatric Cognitive Disorders 2017. DOI: 10.1159/000458521

Participation Size : 72

Traumatic Brain Injury – Neurosurgical pathologies
MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial.

Publication : A. Theadom et al. Eur J Neurol. 2018 Apr 3. DOI: 10.1111/ene.13653

Participation Size : 78

Others
Spinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury.

Publication : Kumar JC et al. JMIR Res Protoc 2016. DOI: 10.2196/resprot.6275

Participation Size : 26

Sponsor : Moleac Pte. Ltd.

The NeuroAiD Safe Treatment (NeST) Registry: a protocol.

Publication : Venketasubramanian N, et al. BJM Open 2015. DOI:10.1136/bmjopen-2015-009866

Participation Size : 460

Sponsor : CHIMES Society

The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES).

Publication : Chen C, et al. Cerebrovasc Dis 2013.DOI: 10.1159/000346234

Participation Size : 103

Sponsor : National University Hospital, Singapore

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial.

Publication : Chen CLH1, Sharma PR2, Tan BY3, Low C4, Venketasubramanian N5. Alzheimers Dement (N Y). 2019 Jan 23;5:38-45. doi: 10.1016/j.trci.2018.12.001

Participation Size : 125